1. Home
  2. NVRI vs NUVB Comparison

NVRI vs NUVB Comparison

Compare NVRI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$22.09

Market Cap

1.6B

Sector

Miscellaneous

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.68

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
NUVB
Founded
1853
2018
Country
United States
United States
Employees
N/A
307
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
NVRI
NUVB
Price
$22.09
$5.68
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
587.3K
7.6M
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.87
$203.82
Revenue Next Year
$3.70
$58.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.70
$1.90
52 Week High
$22.26
$9.75

Technical Indicators

Market Signals
Indicator
NVRI
NUVB
Relative Strength Index (RSI) 58.21 57.50
Support Level $17.79 $4.13
Resistance Level N/A $6.06
Average True Range (ATR) 1.04 0.38
MACD 0.06 0.03
Stochastic Oscillator 90.34 56.51

Price Performance

Historical Comparison
NVRI
NUVB

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: